Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to executive compensation.
Key transaction data points include:
- Share Price: 1,599 pence per Ordinary Share and $52.73 per American Depositary Share (ADS).
- Transaction Date: January 13, 2014 (notification date) following dividend reinvestment on January 9, 2014.
- Participants: Includes Sir Andrew Witty, Mr. S. Dingemans, Dr. M. M. Slaoui, and other senior executives.
Material Changes
The filing details increases in notional interests in Ordinary Shares and ADSs for various executives. These increases resulted from the reinvestment of dividends paid to shareholders. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares acquired by Sir Andrew Witty (2,926 Ordinary Shares total) and other named executives.
- Confirm the share price of 1,599 pence and $52.73 per ADS against market data for January 9, 2014.
- Review the vesting conditions for the deferred annual bonus holdings mentioned in the payout proportionality clause.
- Note that this filing does not contain financial performance data; refer to the company's Form 20-F for comprehensive financial metrics.